{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:49:22Z","timestamp":1770151762789,"version":"3.49.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The phenotypic resistance of selected organisms to ciprofloxacin, levofloxacin, and trovafloxacin was defined as a MIC of \u22654 \u03bcg\/ml. The dynamics of resistance were studied after single and sequential drug exposures: clinical isolates of methicillin-susceptible and methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MSSA and MRSA),\n            <jats:italic>Escherichia coli<\/jats:italic>\n            ,\n            <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n            ,\n            <jats:italic>Enterobacter cloacae<\/jats:italic>\n            ,\n            <jats:italic>Serratia marcescens<\/jats:italic>\n            , and\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            were utilized. After a single 48-h exposure of a large inoculum to four times the initial MIC for the organism, the frequency of selection of resistant mutants of MSSA was greater for trovafloxacin than levofloxacin (\n            <jats:italic>P<\/jats:italic>\n            = 0.008); for\n            <jats:italic>E. cloacae<\/jats:italic>\n            , the frequency was highest for ciprofloxacin and lowest for levofloxacin and trovafloxacin; for\n            <jats:italic>S. marcescens<\/jats:italic>\n            , the frequency was highest for trovafloxacin and lowest for ciprofloxacin (\n            <jats:italic>P<\/jats:italic>\n            = 0.003). The results of serial passage experiments were analyzed both by the Kaplan-Meier product-limited method as well as by analysis of variance of mean inhibitory values. By both methods, MSSA and MRSA expressed mutants resistant to ciprofloxacin after fewer passages than were required for either levofloxacin or trovafloxacin. For the aerobic gram-negative bacilli, two general patterns emerged. Mutants resistant to trovafloxacin appeared sooner and reached higher mean MICs than did mutants resistant to levofloxacin or ciprofloxacin. Mutants resistant to ciprofloxacin appeared later and reached mean MICs lower than the MICs of the other two drugs studied. Even though individual strain variation occurred, the mean MICs were reproduced when the serial passage experiment was repeated using an identical panel of\n            <jats:italic>E. coli<\/jats:italic>\n            isolates. In summary, the dynamic selection of fluoroquinolone-resistant bacteria can be demonstrated in experiments that employ serial passage of bacteria in vitro.\n          <\/jats:p>","DOI":"10.1128\/aac.45.3.883-892.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"883-892","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Phenotypic Resistance of\n            <i>Staphylococcus aureus<\/i>\n            , Selected\n            <i>Enterobacteriaceae<\/i>\n            , and\n            <i>Pseudomonas aeruginosa<\/i>\n            after Single and Multiple In Vitro Exposures to Ciprofloxacin, Levofloxacin, and Trovafloxacin"],"prefix":"10.1128","volume":"45","author":[{"given":"D. N.","family":"Gilbert","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Kohlhepp","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. A.","family":"Slama","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Grunkemeier","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lewis","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Dworkin","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Slaughter","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Leggett","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Earle A. Chiles Research Institute, Providence Portland Medical Center and the Department of Medicine, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","first-page":"273","article-title":"Antibiotic resistance in the intensive therapy unit: the eve of destruction.","volume":"5","author":"Amyes S. G. B.","year":"1995","unstructured":"Amyes S. G. B. Thomson C. J. Antibiotic resistance in the intensive therapy unit: the eve of destruction. Br. J. Intensive Care 5 1995 273 281","journal-title":"Br. J. Intensive Care"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.503"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1007\/BF01793575","article-title":"Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.","volume":"22","author":"Dalhoff A.","year":"1994","unstructured":"Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 22 (Suppl. 2) 1994 S111 S121","journal-title":"Infection"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1862"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/mmbr.61.3.377-392.1997"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2165\/00003495-199500492-00009","article-title":"In vitro activity of fluoroquinolones against gram-positive bacteria.","volume":"49","author":"Eliopoulos G. M.","year":"1995","unstructured":"Eliopoulos G. M. In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs 49 (Suppl. 2) 1995 48 57","journal-title":"Drugs"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/41.2.285","article-title":"Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.","volume":"41","author":"Evans M. E.","year":"1998","unstructured":"Evans M. E. Titlow W. B. Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin. J. Antimicrob. Chemother. 41 1998 285 288","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1917"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2736"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/516303"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/514923"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00007435-199603000-00003","article-title":"Quinolone-resistant Neisseria gonorrheae in Hong Kong.","volume":"23","author":"Kam M. M.","year":"1996","unstructured":"Kam M. M. Wong P. W. Cheung M. M. Ho N. K. Y. Lo K. L. Quinolone-resistant Neisseria gonorrheae in Hong Kong. Sex. Transm. Dis. 23 1996 103 108","journal-title":"Sex. Transm. Dis."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.5.852"},{"key":"e_1_3_1_15_2","first-page":"215","article-title":"Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.","volume":"82","author":"Mulligan M. E.","year":"1987","unstructured":"Mulligan M. E. Ruane P. J. Johnston L. Wong P. Wheelock J. P. MacDonald K. Reinhardt J. F. Johnson C. C. Statner B. Blomquist I. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am. J. Med. 82 1987 215 219","journal-title":"Am. J. Med."},{"key":"e_1_3_1_16_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Antimicrobial susceptibility testing\n          5th ed.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1881"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1001\/archinte.1990.00390210111024","article-title":"Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization.","volume":"150","author":"Peterson L. R.","year":"1990","unstructured":"Peterson L. R. Quick J. N. Jensen B. Homann S. Johnson S. Tenquist J. Stanholtzer C. Petzel R. A. Sinn L. Gerding D. N. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization. Arch. Intern. Med. 150 1990 2151 2155","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/44.5.621","article-title":"Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.","volume":"44","author":"Pong A.","year":"1999","unstructured":"Pong A. Thomson K. S. Moland E. S. Chartrand S. A. Sanders C. S. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J. Antimicrob. Chemother. 44 1999 621 627","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.4.593"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3317"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905203402001"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_1.31"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(99)01001-6","article-title":"Ciprofloxacin-resistant Salmonella typhi and treatment failure.","volume":"353","author":"Threlfall E. J.","year":"1999","unstructured":"Threlfall E. J. Ward L. R. Skinner J. A. Smith H. R. Lacey S. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 353 1999 1590 1591","journal-title":"Lancet"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.3.883-892.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.3.883-892.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:09:17Z","timestamp":1645463357000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.3.883-892.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1128\/AAC.45.3.883-892.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.3.883-892.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]},"assertion":[{"value":"2000-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}